Olivier Tabary

Inserm — France

Medicine · Health Sciences

30h-index2.6kcitations97works0.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cystic Fibrosis Research Advances(58), Neonatal Respiratory Health Research(50), Asthma and respiratory diseases(15), Pediatric health and respiratory diseases(12), Tracheal and airway disorders(10)

Publications97 total

Restoring chloride efflux in cystic fibrosis with TMEM16a antisense oligonucleotides
Molecular Therapy·2025Open Access
P21-21 Exposure To Endocrine Disruptors Exacerbates Osteoarthritic Pain And Inflammatory Responses In A Sex-Dependent Manner
Toxicology Letters·2025
LOCAL EXPOSURE TO ENDOCRINE DISRUPTORS EXACERBATES OSTEOARTHRITIC PAIN AND INFLAMMATORY RESPONSES IN A SEX-DEPENDENT MANNER
Osteoarthritis and Cartilage·2025
Multicentric investigations of the role in the disease severity of accelerated phospholipid changes in COVID-19 patient airway
Microbes and Infection·2024· 3 citedOpen Access
WS17.03 An alternative mutation agnostic therapy for cystic fibrosis with oligonucleotide antisense
Journal of Cystic Fibrosis·2023Open Access
Développement d’une approche antisens pour activer le canal alternatif TMEM16a chez les patients atteints de mucoviscidose
Revue des Maladies Respiratoires·2023
How Much Do We Know About the Mouse Respiratory Epithelial Stem Cells?
Medical Research Archives·2023Open Access
Should We Interfere with the Interleukin-6 Receptor During COVID-19: What Do We Know So Far?
Drugs·2022· 13 citedOpen Access
Étude du potentiel thérapeutique du TSB ANO1 dans la mucoviscidose
Revue des Maladies Respiratoires·2022
Cystic fibrosis affects whole-bone stiffness and strength
SPIRE - Sciences Po Institutional REpository·2021· 1 cited
TMEM16A/ANO1: Current Strategies and Novel Drug Approaches for Cystic Fibrosis
Cells·2021· 17 citedOpen Access
Novel Anti-Inflammatory Approaches for Cystic Fibrosis Lung Disease: Identification of Molecular Targets and Design of Innovative Therapies
Frontiers in Pharmacology·2020· 44 citedOpen Access
miR-636: A Newly-Identified Actor for the Regulation of Pulmonary Inflammation in Cystic Fibrosis
Frontiers in Immunology·2019· 18 citedOpen Access
Emerging microRNA Therapeutic Approaches for Cystic Fibrosis
Frontiers in Pharmacology·2018· 34 citedOpen Access
Opposite Expression of Hepatic and Pulmonary Corticosteroid-Binding Globulin in Cystic Fibrosis Patients
Frontiers in Pharmacology·2018· 4 citedOpen Access
Mucoviscidose : dans la ligne des miR
médecine/sciences·2018· 1 citedOpen Access
Small RNA and transcriptome sequencing reveal the role of miR‐199a‐3p in inflammatory processes in cystic fibrosis airways
The Journal of Pathology·2018· 40 citedOpen Access
MicroRNA-9 downregulates the ANO1 chloride channel and contributes to cystic fibrosis lung pathology
Nature Communications·2017· 70 citedOpen Access
WS06.5 New insights into the pathogenesis and potential therapies of cystic fibrosis (CF) bone disease
Journal of Cystic Fibrosis·2016Open Access
Normal and Cystic Fibrosis Human Bronchial Epithelial Cells Infected with Pseudomonas aeruginosa Exhibit Distinct Gene Activation Patterns
PLoS ONE·2015· 32 citedOpen Access
page 1 of 5Next →

Frequent Co-authors

Jacky Jacquot(28), Annick Clément(23), Harriet Corvol(21), Loïc Guillot(13), Philippe Le Rouzic(12), Émilie Boncoeur(7), Édith Puchelle(6), Manon Ruffin(6), Vinciane Saint‐Criq(6), Katarina Chadelat(5), Sandie Escotte‐Binet(5), Daniel Dusser(5), Telma Roque(5), Elise Bonvin(5), D. Hubert(4), Florence Sonneville(4), Nathalie Rousselet(4), M. Bonora(4), Alexandra Henrion‐Caude(4), Pauline Bardin(4)